There are specific recommendations for dose modifications related to particular adverse reactions. Click on an adverse reaction below to see the recommendations.
Severity1 | Guidance1 |
---|---|
MILD Cholesterol ULN-300 mg/dL OR Triglycerides 150-300 mg/dL OR MODERATE Cholesterol 301-400 mg/dL OR Triglycerides 301-500 mg/dL |
|
SEVERE Cholesterol 401-500 mg/dL OR Triglycerides 501-1000 mg/dL |
|
LIFE-THREATENING Cholesterol >500 mg/dL OR Triglycerides >1000 mg/dL |
|
Severity1 | Guidance1 |
---|---|
Grade 2: Moderate OR Grade 3: Severe |
|
Grade 4: Life-threatening/urgent intervention indicated |
|
Severity1 | Guidance1 |
---|---|
Grade 3: Severe OR Grade 4: Life-threatening/urgent intervention indicated |
|
Severity1 | Guidance1 |
---|---|
Grade 1: Mild OR Grade 2: Moderate |
|
Grade 3: Severe OR Grade 4: Life-threatening/urgent intervention indicated |
|
Severity1 | Guidance1 |
---|---|
First-degree AV block: Asymptomatic |
|
First-degree AV block: Symptomatic |
|
Severity1 | Guidance1 |
---|---|
Second-degree AV block: Asymptomatic |
|
Second-degree AV block: Symptomatic |
|
Severity1 | Guidance1 |
---|---|
Complete AV block |
|
Blood pressure should be controlled prior to initiation of LORVIQUA and monitored after 2 weeks and at least monthly thereafter during treatment with LORVIQUA.1
Severity1 | Guidance1 |
---|---|
Grade 3:
|
|
Grade 4: Life-threatening consequences, urgent intervention indicated |
|
Fasting serum glucose should be assessed prior to initiation of LORVIQUA and monitored periodically thereafter.1
Severity1 | Guidance1 |
---|---|
Grade 3 OR Grade 4: Persistent hyperglycaemia >250 mg/dL despite optimal antihyperglycaemic therapy |
|
Fasting serum glucose should be assessed prior to initiation of LORVIQUA and monitored periodically thereafter.1
Severity1 | Guidance1 |
---|---|
Grade 1: Mild OR Grade 2: Moderate |
|
≥Grade 3: Severe |
|
Pfizer. LORVIQUA (lorlatinib) Summary of Product Characteristics.
The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.
I confirm that I am a healthcare professional* resident in the Republic of Ireland.
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses
Terms of use
PP-UNP-IRL-0784. June 2024